RESCEU and PROMISE projects
RESCEU was a 5 year EU wide consortium (2017-2022) funded by the Innovative Medicines Initiative (IMI), a European Commission and European Federation of Pharmaceutical Industries and Associations partnership, to deepen our understanding of RSV and generate more comprehensive data on RSV in Europe.
With the anticipated licensure and subsequent market availability of RSV immunizations by 2025, PROMISE was funded by IMI in 2021 to build on RESCEU's achievements and address remaining key questions to inform the introduction of RSV immunization in Europe.
Both projects were led (co-ordinated) by Professor Harish Nair at the Usher Institute, The University of Edinburgh. The results from these two projects have informed policy on RSV surveillance and recommendations for implementation of RSV vaccines and monoclonal antibodies in national immunization programs across Europe. Another notable highlight of the projects was the launch of the RSV awareness week, spearheaded by the consortium's Patient Advisory Board, to raise public awareness and understanding of the virus.
Details of both projects are maintained on this website as an archive, although all work on these studies is now complete.
If you are interested in finding out more about RSV, consider contacting the RSV patient network.
The RESCEU project aimed to develop robust evidence on RSV disease burden and economic impact; create a sustainable Europe-wide multidisciplinary, multi-stakeholder community from academia, public health, scientific societies, patient organisations, regulatory agencies and industry; and provide infrastructure to perform future pivotal trials for RSV vaccines and therapeutics.
Funded by the Innovative Medicines Initiative (IMI), this initiative focused on advancing scientific knowledge on RSV to inform public health strategies and bolster the development and introduction of novel immunisations tools and therapeutics in Europe.
Respiratory Syncytial Virus (RSV) is a highly infectious respiratory illness, with babies, young children and the elderly most at risk.
See an archive collection of RESCEU's publications.
Find out about the RSV Patient Network, including their engagement sessions, surveys and more.